Details

Autor(en) / Beteiligte

• Corrà, Ugo
• Agostoni, Piergiuseppe
• Giordano, Andrea
• Cattadori, Gaia
• Battaia, Elisa
• La Gioia, Rocco
• Scardovi, Angela B
• Emdin, Michele
• Metra, Marco
• Sinagra, Gianfranco
• Limongelli, Giuseppe
• Raimondo, Rosa
• Re, Federica
• Guazzi, Marco
• Belardinelli, Romualdo
• Parati, Gianfranco
• Magrì, Damiano
• Fiorentini, Cesare
• Cicoira, Mariantonietta
• Salvioni, Elisabetta
• Giovannardi, Marta
• Veglia, Fabrizio
• Mezzani, Alessandro
• Scrutinio, Domenico
• Di Lenarda, Andrea
• Ricci, Roberto
• Apostolo, Anna
• Iorio, Anna Maria
• Paolillo, Stefania
• Palermo, Pietro
• Contini, Mauro
• Vassanelli, Corrado
• Passino, Claudio
• Giannuzzi, Pantaleo
• Piepoli, Massimo F
• Antonioli, Laura
• Segurini, Chiara
• Bertella, Erica
• Farina, Stefania
• Bovis, Francesca
• Pietrucci, Francesca
• Malfatto, Gabriella
• Roselli, Teo
• Buono, Andrea
• Calabrò, Raffaele
• De Maria, Renata
• Santoro, Daniela
• Campanale, Saba
• Caputo, Domenica
• Bertipaglia, Donatella
• Berton, Emanuela

Titel

The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study

Ist Teil von

• International journal of cardiology, 2016-01, Vol.203, p.1067-1072

Ort / Verlag

Netherlands: Elsevier Ireland Ltd

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Background The Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score is a prognostic model to identify heart failure (HF) patients at risk for cardiovascular mortality (CVM) and urgent heart transplantation (uHT) based on 6 routine clinical parameters: hemoglobin, sodium, kidney function by the Modification of Diet in Renal Disease (MDRD) equation, left ventricle ejection fraction (LVEF), percentage of predicted peak oxygen consumption (VO2) and VE/VCO2 slope. Objectives MECKI score must be generalizable to be considered useful: therefore, its performance was validated in a new sequence of HF patients. Methods Both the development (MECKI-D) and the validation (MECKI-V) cohorts were composed of consecutive HF patients with LVEF < 40% able to perform a symptom-limited cardiopulmonary exercise testing. The CVM or uHT rates were analyzed at one, two and three years in both cohorts: all patients with a censoring time shorter than the scheduled follow-up were excluded, while those with events occurring after 1, 2 and 3 years were considered as censored. Results MECKI-D and MECKI-V consisted of 2009 and 992 patients, respectively. MECKI-V patients had a higher LVEF, higher peak VO2 and lower VE/VCO2 slope, higher prescription of beta-blockers and device therapy: after the 3-year follow-up, CVM or uHT occurred in 206 (18%) MECKI-D and 44 (13%) MECKI-V patients (p < 0.000), respectively. MECKI-V AUC values at one, two and three years were 0.81 ± 0.04, 0.76 ± 0.04, and 0.80 ± 0.03, respectively, not significantly different from MECKI-D. Conclusions MECKI score preserves its predictive ability in a HF population at a lower risk.